Semaglutide for MASH: MENA Review

A 2026 Middle East and North Africa expert-panel review translates new MASH drug evidence into regional questions about patient selection, monitoring and access. It is not a new treatment trial. For semaglutide, the main efficacy evidence comes from the randomized phase 3 ESSENCE study, where an interim biopsy analysis favored semaglutide over placebo on both primary liver-histology outcomes.^[1]

The regional paper discusses both semaglutide and resmetirom for non-cirrhotic MASH with fibrosis stages 2 or 3. Its central implementation point is plain: regulatory status, cost and healthcare infrastructure will shape whether trial efficacy becomes real access across MENA countries.^[1] That context should not be confused with a recommendation for self-treatment.

What the MENA panel actually produced

The seed article is an expert review. A regional panel searched PubMed and Google Scholar for clinical trials and international guidance on resmetirom and semaglutide. The review identifies a target treatment population, proposes circumstances for stopping therapy, outlines monitoring and maps regional knowledge gaps.^[1] The abstract does not report a consensus-voting method or new patient outcomes.

This evidence design matters. Expert panels can interpret trial evidence for a health system and flag practical barriers that a multinational trial does not answer. Their recommendations still depend on the quality and applicability of the underlying trials. They should not be described as though the panel independently tested either medicine in MENA patients.

The paper uses MAFLD in its title and discusses MASH treatment. Nomenclature has shifted across liver societies, and readers may also see MASLD used for metabolic dysfunction-associated steatotic liver disease. Whatever label is used, the drug discussion here concerns a narrower group with steatohepatitis and moderate-to-advanced fibrosis, not everyone with liver fat.

The semaglutide evidence comes from ESSENCE

ESSENCE is an ongoing multicenter, double-blind, placebo-controlled phase 3 trial. Investigators randomized 1,197 adults with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks. The published report covers a planned week-72 interim analysis in the first 800 participants.^[2]

The first primary endpoint was resolution of steatohepatitis without worsening fibrosis. It occurred in 62.9% of the 534 semaglutide participants and 34.3% of the 266 placebo participants, an estimated difference of 28.7 percentage points. The 95% confidence interval ran from 21.1 to 36.2 percentage points.^[2]

The second primary endpoint was at least one stage of fibrosis improvement without worsening steatohepatitis. That outcome occurred in 36.8% with semaglutide and 22.4% with placebo. The estimated difference was 14.4 percentage points, with a 95% confidence interval from 7.5 to 21.3.^[2] Both primary histology outcomes therefore favored treatment at the interim analysis.

Secondary findings and safety context

Combined steatohepatitis resolution and fibrosis improvement occurred in 32.7% of semaglutide participants and 16.1% of placebo participants. Mean body weight changed by minus 10.5% with semaglutide and minus 2.0% with placebo. Bodily pain scores did not differ significantly between groups.^[2]

Gastrointestinal adverse events were more common with semaglutide.^[2] The abstract does not supply the event-by-event rates, discontinuation details or subgroup safety profile. Those gaps matter when applying a long-duration regimen in health systems where specialist follow-up, medicine supply and management of adverse effects vary.

The reported 2.4 mg weekly regimen describes the randomized trial. It is not a dosing instruction. ESSENCE eligibility depended on biopsy-defined disease and fibrosis stage, while real clinical decisions may also use non-invasive tests and jurisdiction-specific product information. Treatment belongs with clinicians who can evaluate liver stage, contraindications, other medicines and monitoring capacity.

Why MENA implementation needs its own lens

The panel describes fatty liver disease prevalence of 25% to 30% globally and rates reaching 40% in parts of the MENA region.^[1] Prevalence estimates depend on definition and measurement, but the regional burden explains why access planning has become urgent. A therapy can meet trial endpoints and still have little population effect if diagnosis, fibrosis staging or specialist care is unavailable.

Cost is not a side issue. Semaglutide and resmetirom have different mechanisms, evidence packages and monitoring considerations. The panel argues that individualized pathways must account for affordability, local regulatory status and healthcare infrastructure. A recommendation developed for one country's reimbursement system cannot simply be copied across a region with varied approvals and coverage.

Regional evidence is also limited. A global phase 3 population may include participants from several settings, but the PubMed abstracts do not provide a MENA-specific efficacy estimate for ESSENCE. Local registries and prospective studies could show whether diagnostic pathways, comorbidities, adherence or access alter outcomes after approval.

How to read the two-drug framing

The review places resmetirom and semaglutide in the same implementation discussion because both entered the MASH treatment landscape. That does not make them interchangeable. Nor does it establish a combination strategy. Comparing or sequencing them requires attention to approved labeling, fibrosis stage, metabolic indications, contraindications and the endpoints each evidence program measured.

For readers following semaglutide, our semaglutide research overview separates trial evidence from broader claims, while the semaglutide safety guide covers adverse-effect context. Country-specific approval questions belong in the semaglutide regulation section, because an FDA decision does not automatically apply elsewhere.

The term conditional approval in the panel abstract should also be read against current official labeling in the relevant jurisdiction. The panel offers a regional synthesis published at one point in time. Regulators can approve different populations, require different monitoring or update labels as longer follow-up arrives.

What we do not know yet

ESSENCE is ongoing for 240 weeks, so the week-72 publication is not the final long-term readout. Histology endpoints improved, but we still need the mature trial to clarify durability and later clinical outcomes. The interim analysis also does not resolve which eligible patients gain the most, how response should be monitored outside a trial or when a lack of response should prompt a change.

For the MENA region, the central unknown is implementation. The expert review identifies target-population and monitoring questions, yet its abstract does not supply region-specific effectiveness or affordability data. Those answers will require local evidence rather than extrapolation alone.

The evidence hierarchy is therefore clear. ESSENCE supplies randomized semaglutide efficacy data in biopsy-defined MASH with stage 2 or 3 fibrosis. The MENA panel interprets that evidence for regional practice and access. Both are useful, but they answer different questions.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.